Clinical trials: Infection Resistant to Multiple Drugs, open to volunteers
Multi Drug Resistant Tuberculosis, HIV Infections
An Adaptive Randomized Controlled Trial
This is a prospective, adaptive, randomized controlled trial comparing the effectiveness of 4 intervention arms on a combined endpoint in adults with confirmed MDR-TB HIV initiating Bedaquiline-containing MDR-TB treatment…
- Trial name
- ADAP-TIV (NCT05633056)
- Testing
- Adherence support intevention
- Where
- South Africa
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Columbia University
MDR-TB, Tuberculosis Multi Drug Resistant Active
Feasibility of the Application of a New Six-month Treatment for Multidrug-resistant Tuberculosis (MDR-TB) Patients in France (FAST-MDR)
The FAST-MDR trial is an externally-controlled, multicentre trial with one prospective arm, evaluating the non-inferiority of the effectiveness of BPaLM in the interventional arm versus the effectiveness of the long, conventional…
- Conditions
- MDR-TB, Tuberculosis Multi Drug Resistant Active, Antibiotic Resistance, Mycobacterium Tuberculosis
- Trial name
- FAST-MDR (NCT07486024)
- Testing
- Bedaquiline Oral Tablet
- Where
- 5 sites in France
- Volunteers
- 55 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Clostridium Infections, Methicillin-resistant Staphylococcus Aureus (MRSA)
A Clinical Trial of Resistant Potato Starch for Gut MDRO Decolonization
Multidrug-resistant organisms (MDROs) cause serious infections that are difficult to treat, leading to increased morbidity and mortality, longer hospital stays, and increased healthcare costs.
- Conditions
- Clostridium Infections, Methicillin-resistant Staphylococcus Aureus (MRSA), Vancomycin-Resistant Enterococci, Carbapenem-Resistant Enterobacteriaceae
- Trial name
- MDRO-Fiber (NCT07792915)
- Testing
- Resistant Potato Starch, Maltodextrin
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- VA Office of Research and Development
Pulmonary Tuberculosis
A PAN-USR TB Multi-Center Trial
Tuberculosis (TB) remains a major public health issue and one of the top ten causes of death from a single infectious disease worldwide.
- Trial name
- NCT06905522
- Testing
- Bedaquiline (B), Sitafloxacin (S), Linezolid (L)
- Where
- 3 sites in China
- Volunteers
- 610 people
- Sponsor
- Shenzhen Third People's Hospital
Pseudomonas Infections, Pseudomonas Aeruginosa
Antimicrobial Therapy for Difficult-to-treat Pseudomonas Aeruginosa
The primary objective of the ADDICT study is to assess and compare the clinical efficacy of available options for antimicrobial therapy (new beta-lactam/beta-lactamase inhibitor combination, cefiderocol or older agents such as…
- Conditions
- Pseudomonas Infections, Pseudomonas Aeruginosa, Prognosis, Drug Resistance, Multiple, Bacterial
- Trial name
- ADDICT (NCT06738771)
- Where
- 48 sites in France, Reunion
- Volunteers
- 600 people
- Sponsor
- Centre Hospitalier Régional d'Orléans
Multidrug-resistant Tuberculosis (MDR-TB)
Molecular Epidemiology, Strains Genotyping of Multi-drug Resistant Tuberculosis Circulating in Central Africa Region
Multidrug-resistant tuberculosis (MDR-TB) poses a significant challenge in Central Africa. Understanding the molecular epidemiology and genotypic characteristics of MDR-TB strains is crucial for effective control measures.
- Trial name
- MESTCAR (NCT07017803)
- Where
- 8 sites in Gabon
- Volunteers
- 460 people, healthy volunteers welcome
- Sponsor
- Centre de Recherche Médicale de Lambaréné
Tuberculosis, Multidrug-Resistant
Bioneer Q-RFIA Clinical Evaluation
Robust evidence on the clinical diagnostic accuracy and operational characteristics of the Bioneer Accupower Q-RFIA PCR kit on IRON qPCR is required to comprehensively evaluate validity of the Bioneer RFIA assay to support both…
- Trial name
- NCT05117788
- Testing
- Estimate the diagnostic accuracy of the Bioneer Accupower Q-RFIA PCR kit on IRON qPCR for MTB detection using culture as reference standard. Estimate the diagnostic accuracy of the Bioneer Ac
- Where
- 5 sites in Kenya, Moldova and 3 more
- Volunteers
- 2,350 people
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
Fecal Microbiota Transplantation, Orthotopic Liver Transplantation
Fecal Microbiota Transplantation for the Prevention of Infectious Complications After Liver Transplantation
The increasing emergence and spread of MDRB represents a major public health problem, with higher mortality in patients experiencing infections.
- Conditions
- Fecal Microbiota Transplantation, Orthotopic Liver Transplantation, Multi-drug Resistant Bacteria
- Trial name
- NCT06782880
- Testing
- Fecal microbiota transplantation (FMT)
- Where
- Italy
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Enterobacteriaceae Infections, Carbapenem-Resistant Enterobacteriaceae Infection
Aztreonam-Avibactam in Immunocompromised Hosts
The goal of this observational study is to learn about the effectiveness and safety of aztreonam-avibactam (ATM-AVI), an antibiotic used to treat infections caused by highly resistant bacteria, in adults with weakened immune…
- Conditions
- Enterobacteriaceae Infections, Carbapenem-Resistant Enterobacteriaceae Infection, Immunocompromised Host, Drug Resistance, Multiple, Bacterial
- Trial name
- IMMUNO-AVI (NCT07890480)
- Testing
- Aztreonam-Avibactam, Ceftazidime-Avibactam Plus Aztreonam
- Where
- Argentina
- Volunteers
- 814 people
- Sponsor
- Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno
Intestinal Multi-drug Resistant Organism Colonization
Further MT for Antibiotic-Resistant Bacterial Colonization
The purpose of this study is to better understand the effectiveness and safety of microbiome therapies (MT) as a treatment for patients with Multidrug Resistant Organism (MDRO) colonization after an infection.
- Trial name
- FAIR (NCT05835206)
- Testing
- Microbiome Therapeutic
- Where
- 6 sites in United States
- Volunteers
- 40 people
- Sponsor
- Emory University
Multi Drug Resistant Organisms
Infection Risk Associated With Digestive MDRO Carriage in Hospitalized Patients
This study aims to evaluate the impact of digestive carriage of multidrug-resistant organisms (MDRO) on the risk of healthcare-associated infections in hospitalized adult patients.
- Trial name
- NCT07134270
- Testing
- MDRO Rectal Screening, 30-Day Telephone Follow-Up
- Where
- Romania
- Volunteers
- 400 people
- Sponsor
- Valeriu Gheorghita
Critical Ill Patients, Multi Drug Resistant
Different Dosing Strategies of Colistin in Multidrug-Resistant Gram-Negative Bacilli Infections
Nosocomial infections caused by multi-drug-resistant (MDR) and extensively drug-resistant (XDR) Gram-negative pathogens represent a major threat worldwide.
- Trial name
- NCT06843668
- Testing
- EMA colistin dosing strategy, US FDA colistin dosing strategy
- Where
- Saudi Arabia
- Volunteers
- 120 people
- Sponsor
- Mansoura University
Multi Drug Resistant Infections, Pneumnia
Traditional Chinese Medicine in Multidrug-Resistant Bacterial Pneumonia
This is a multicenter prospective observational cohort study involving hospitalized adult patients with multidrug-resistant bacterial pneumonia.
- Trial name
- MDRBP-TCM (NCT07726095)
- Where
- China
- Volunteers
- 652 people
- Sponsor
- Henan University of Traditional Chinese Medicine
Enterobacteriaceae Infections, Multi-antibiotic Resistance
FMT for the Decolonization of Carbapenem-resistant Enterobacteriaceae
Rates of antimicrobial resistance are increasing worldwide. There is increasing evidence that physiological gut microbiota is a large reservoir of antibiotic-resistance genes.
- Trial name
- FMT-CRE (NCT04759001)
- Testing
- Donor FMT
- Where
- Italy
- Volunteers
- 52 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Linezolid, Tuberculosis Multi Drug Resistant Active
Linezolid Tolerance During the BPaL Regimen With Dosage Personalization Based on Therapeutic Drug Monitoring (TDM) During Multidrug-Resistant Tuberculosis Treatment
Multidrug-resistant tuberculosis (MDR-TB) poses a significant challenge to global public health. Globally, the World Health Organization (WHO) estimates the number at 400,000 patients with MDR-TB for 2023.
- Conditions
- Linezolid, Tuberculosis Multi Drug Resistant Active, Therapeutic Drug Monitoring (TDM)
- Trial name
- PLOT-TB (NCT07477119)
- Testing
- Linezolid dose personalization based on TDM
- Where
- Guinea
- Volunteers
- 150 people
- Sponsor
- Marco Schiuma
Enterobacteriaceae Infections, Multi-antibiotic Resistance
FMT to Eradicate Intestinal Colonization by Carbapenem-resistant Enterobacteriaceae
Antibiotic resistance (AR) is a critical public health threat and one of the greatest challenges of the 21st century. In an estimate of 2019, nearly 700.000 infections and 33.000 attributable deaths from multi-drug-resistant…
- Trial name
- FMT_CRE (NCT05791396)
- Testing
- Donor - FMT
- Where
- Italy
- Volunteers
- 36 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Tuberculosis, Multidrug-Resistant
Registry on the Effectiveness and Safety of the 9-month MDR-END Treatment Regimen in Korean Patients with FQ-sensitive MDR-TB (MDR-END Registry)
This study is to evaluate the effectiveness and safety of a 9-month MDR-END regimen as a treatment for fluoroquinolone-sensitive multidrug resistant pulmonary tuberculosis in the real-world clinical setting.
- Trial name
- NCT06674291
- Testing
- No intervention (observational study)
- Volunteers
- 222 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Multidrug Resistant Klebsiella Pneumoniae Infection
Phenotypic and Genotypic Detection of Biofilm Formation and Efflux Pump Activity in Multi-drug Resistant Klebsiella Pneumoniae
1. Sample: urine, pus and sputum samples. 2. Culture: the samples will be inoculated on the MacConkey agar and subcultured on eosine methylene blue agar. 3. Identification of isolates will be done by: Colony morphology.
- Trial name
- Klebsiella (NCT07541690)
- Testing
- Genotypic Detection of Biofilm Formation and Efflux Pump Activity.
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Sohag University
HIV Infection
Prevalence of Drug-resistant Hiv-1 Strains in Patients Experiencing Virologic Failure. (MULTIVIR2025)
In this cross-sectional, national and multicenter study, the main objective is to determine the prevalence of multi-drug resistant viruses (i.e., viruses that are resistant or possibly resistant to at least one antiretroviral…
- Trial name
- MULTIVIR2025 (NCT06842706)
- Volunteers
- 800 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV-1-infection, Multi-Antiviral Resistance
Italian Registry of HIV-1 Infected Patients With Drug-RESistant Virus to Reverse Transcriptase Inhibitors, InteGrasE and Viral Protease.
The PRESTIGIO Registry is an Observational, prospective, multicentre study that includes patients, regularly followed by Italian Infectious Disease Centres, with HIV-1 infection and documented resistance to the 4 classes of…
- Trial name
- PRESTIGIO (NCT04098315)
- Testing
- REGISTER CREATION
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- Castagna Antonella